Serum HE4 predicts progestin treatment response in endometrial cancer and atypical hyperplasia: A prognostic study.
Chloe E BarrJamie C SergeantHeather J AgnewJames BoltonRhona J McVeyEmma J CrosbiePublished in: BJOG : an international journal of obstetrics and gynaecology (2023)
Serum HE4 shows promise as a predictive biomarker of progestin treatment response in endometrial cancer and AEH.